- Secures approval for 'Hunterase IV' in India and both 'Hunterase IV & ICV' in Taiwan, accelerating expansion into the Asian rare disease market YONGIN, South Korea, Aug. 24, 2026 /PRNewswire/ -- GC Biopharma (006280.KS), a leading global pharmaceutical company based in South Korea,...
Hence then, the article about gc biopharma s hunter syndrome treatment hunterase receives drug approval in india and taiwan was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( GC Biopharma's Hunter Syndrome Treatment 'Hunterase' Receives Drug Approval in India and Taiwan )
Also on site :
- Guitar Center is dropping its ban on playing ‘Stairway to Heaven.’ It’s part of the CEO’s big turnaround plan
- Vietnamese Horror ‘Arithmadtic’ Leads Bee Entertainment’s Busan Market Slate, With New Film From ‘The Corpse’ Director
- Pentagon to livestream firing-squad execution of US Army psychiatrist who killed 13 in 2009 attack: Inside the scrutinized plan